Transthyretin cardiac amyloidosis: A treatable form of heart failure with a preserved ejection fraction

Cardiac amyloidosis (CA) is considered a rare disease with poor prognosis and limited therapeutic options. However, non-biopsy diagnostic modalities as well as emerging therapies are challenging this long-held belief. Radionuclide bone scintigraphy is increasingly being used in the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CA). As such, it is expected that the number of patients diagnosed with ATTR-CA will continue to rise. Emerging therapies decrease the progressive morbidity and mortality associated with ATTR-CA. The importance of early recognition of ATTR-CA is imperative as prompt initiation of these novel agents is essential to maximize their therapeutic potential. Herein, we outline the current approach to diagnosis of ATTR-CA and review the therapeutic management of the disease. (C) 2019 Elsevier Inc. All rights reserved.

Automated summary

Cardiac amyloidosis is a rare disease with limited therapeutic options, but advancements in diagnostic modalities and emerging therapies are challenging the traditional beliefs about its prognosis. Early recognition and prompt initiation of novel agents are crucial in improving the outcomes for patients with ATTR-CA.